← Back to Search

Imaging

MRI Scans for Prostate Cancer

Q: How many participants can take part in the research endeavor?

<p>Affirmative. The clinical trial, first posted on April 20th 2016, is actively seeking new participants as per the data hosted by clinicaltrials.gov. A total of 86 patients are required from 1 medical centre for this study to be completed successfully.</p>

Q: Are any new patients being accepted for this investigation?

<p>This clinical trial is currently open for recruitment, as indicated by the information on clinicaltrials.gov. It was initially announced in April 2016 and its sponsor recently updated it in August of 2020.</p>

N/A

Waitlist Available

Led By Tharakeswara K Bathala

Research Sponsored by M.D. Anderson Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Prostate carcinoma patients at high risk for metastasis with prostate-specific antigen (PSA) more than 20 ng/ml and/or Gleason score = 8/ > 8

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 9 years

Awards & highlights

Study Summary

This trial is testing how effective magnetic resonance whole body diffusion-weighted imaging is at finding cancer that has spread to the bone or lymph nodes in participants with high-risk prostate cancer.

Who is the study for?

This trial is for individuals with high-risk prostate cancer, specifically those who have a PSA level over 20 ng/ml and/or a Gleason score of 8 or higher. Participants must be able to understand and sign consent. It's not for those on testosterone suppressing drugs, previous radiation therapy, low-risk patients (Gleason score < 8), or anyone who can't undergo MRI.Check my eligibility

What is being tested?

The study is testing the effectiveness of magnetic resonance whole body diffusion-weighted imaging in detecting the spread of prostate cancer to bones or lymph nodes compared to traditional bone scans and CT scans.See study design

What are the potential side effects?

Since this trial involves diagnostic procedures like MRIs rather than medications, side effects are minimal but may include discomfort from lying still during the scan or reactions if contrast agents are used.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My PSA level is over 20 ng/ml or my Gleason score is 8 or higher, indicating high-risk prostate cancer.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 9 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 9 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 9 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Accuracy of whole body magnetic resonance imaging (MRI)

Secondary outcome measures

Detection of other types of metastases

Negative predictive value (NPV) of MRI, bone scan, and CT scan

Positive predictive value (PPV) of MRI, bone scan, and CT scan

+2 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: Diagnostic (bone scan, CT, MRI, magnetic resonance WB-DWI)Experimental Treatment4 Interventions

Participants undergo standard of care bone scan, CT of the abdomen and pelvis, and pelvic MRI. Participants also undergo magnetic resonance WB-DWI over 20-30 minutes.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Computed Tomography

2017

Completed Phase 2

~2720

Magnetic Resonance Imaging

2017

Completed Phase 3

~1190

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor

2,966 Previous Clinical Trials

1,804,683 Total Patients Enrolled

95 Trials studying Prostate Cancer

29,642 Patients Enrolled for Prostate Cancer

National Cancer Institute (NCI)NIH

13,654 Previous Clinical Trials

40,933,055 Total Patients Enrolled

560 Trials studying Prostate Cancer

507,075 Patients Enrolled for Prostate Cancer

Tharakeswara K BathalaPrincipal InvestigatorM.D. Anderson Cancer Center

Media Library

Magnetic Resonance Whole Body Diffusion-Weighted Imaging (Imaging) Clinical Trial Eligibility Overview. Trial Name: NCT03085043 — N/A

Prostate Cancer Research Study Groups: Diagnostic (bone scan, CT, MRI, magnetic resonance WB-DWI)

Prostate Cancer Clinical Trial 2023: Magnetic Resonance Whole Body Diffusion-Weighted Imaging Highlights & Side Effects. Trial Name: NCT03085043 — N/A

Magnetic Resonance Whole Body Diffusion-Weighted Imaging (Imaging) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03085043 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants can take part in the research endeavor?

"Affirmative. The clinical trial, first posted on April 20th 2016, is actively seeking new participants as per the data hosted by clinicaltrials.gov. A total of 86 patients are required from 1 medical centre for this study to be completed successfully."

Answered by AI

Are any new patients being accepted for this investigation?

"This clinical trial is currently open for recruitment, as indicated by the information on clinicaltrials.gov. It was initially announced in April 2016 and its sponsor recently updated it in August of 2020."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Magnetic Resonance Whole Body Diffusion-Weighted Imaging in Finding Bone or Lymph Node Metastasis in Participants With High-Risk Prostate Cancer

2016. "Magnetic Resonance Whole Body Diffusion-Weighted Imaging in Finding Bone or Lymph Node Metastasis in Participants With High-Risk Prostate Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03085043.

All > Prostate Cancer Houston